Dynamic changes of monocytes subsets predict major adverse cardiovascular events and left ventricular function after...

Area of Science:

• Cardiology
• Immunology
• Biomedical Research

Background:

• ST-elevation myocardial infarction (STEMI) is a critical cardiovascular event with significant morbidity and mortality.
• Monocyte subsets play a role in post-infarction inflammation and cardiac remodeling, but their dynamic changes are not well understood.
• Understanding the prognostic value of dynamic monocyte subset changes is crucial for risk stratification and therapeutic development.

Purpose of the Study:

• To investigate the relationship between dynamic changes in monocyte subset counts, phagocytic activity, and NFκB activity with major adverse cardiovascular events (MACE) and left ventricular ejection fraction (LVEF) in STEMI patients.
• To determine if specific patterns of monocyte subset dynamics predict clinical outcomes and cardiac function recovery post-STEMI.

Main Methods:

• Flow cytometry was used to measure monocyte subset counts (Mon1, Mon2, Mon3), phagocytic activity, and inhibitory κB kinase β (IKKβ) levels at baseline, 1 week, 2 weeks, and 1 month post-STEMI.
• Left ventricular ejection fraction (LVEF) was assessed by echocardiography at baseline and 6 months post-STEMI.
• Multivariate Cox regression analysis was employed to evaluate the association between dynamic monocyte changes and clinical outcomes in 245 STEMI patients followed for a median of 46 months.

Main Results:

• A more prominent dynamic reduction in the Mon2 subset by week 1 was independently associated with a lower risk of MACE (HR 0.06, p=0.01).
• Less prominent reduction in Mon2 subset counts by month 1 was independently predictive of better 6-month LVEF.
• No significant associations were found between dynamic changes in other monocyte subsets, phagocytic activity, or IKKβ levels and MACE or LVEF.

Conclusions:

• Distinct dynamic changes in the Mon2 monocyte subset are significantly related to both MACE risk and cardiac contractility recovery following STEMI.
• The prognostic value of Mon2 subset dynamics highlights its potential as a biomarker for cardiovascular risk and recovery after myocardial infarction.
• Further research is warranted to elucidate the underlying mechanisms and explore pharmacological interventions targeting monocyte subsets for improved STEMI patient outcomes.